{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:41:14Z","timestamp":1792683674406,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.cpcardiol.2022.101461","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T07:42:38Z","timestamp":1665992558000},"page":"101461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"48","author":[{"given":"Amudha","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjith K.","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Chidambaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie G.","family":"Majella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Adamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhi J.","family":"Al'Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-2097","authenticated-orcid":false,"given":"Jawahar L.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101461_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004005","article-title":"Heart failure in pregnant women: a concern across the pregnancy continuum","volume":"11","author":"Mogos","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0002","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/heartjnl-2018-313156","article-title":"Maternal and fetal outcomes in pregnant women with heart failure","author":"Ng","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0003","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/eurjhf\/hfq120","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy","volume":"12","author":"Sliwa","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0004","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1253\/circj.CJ-10-1214","article-title":"Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders: results from the Japanese nationwide survey of peripartum cardiomyopathy","volume":"75","author":"Kamiya","year":"2011","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0005","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.4314\/ahs.v17i4.15","article-title":"Cardiovascular risk factors in adult general out-patient clinics in Nigeria: a country analysis of the Africa and Middle East Cardiovascular Epidemiological (ACE) study","volume":"17","author":"Onyemelukwe","year":"2017","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0006","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/01.CIR.0000162478.36652.7E","article-title":"Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation","volume":"111","author":"Elkayam","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0007","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2015.06.1309","article-title":"Clinical outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)","volume":"66","author":"McNamara","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0167-5273(02)00359-5","article-title":"Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection","volume":"86","author":"Fett","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0009","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ajog.2005.01.022","article-title":"High prevalence of viral genomes and inflammation in peripartum cardiomyopathy","volume":"193","author":"B\u00fcltmann","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0010","article-title":"Peripartum cardiomyopathy","volume":"364","author":"Honigberg","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0011","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1161\/hc3401.095947","article-title":"Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia\/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase","volume":"104","author":"Negoro","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0012","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature11040","article-title":"Cardiac angiogenic imbalance leads to peripartum cardiomyopathy","volume":"485","author":"Patten","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0013","doi-asserted-by":"crossref","unstructured":"Bozkurt B, Colvin M, Cook J, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement from the American Heart Association. 134. 2016. doi:10.1161\/CIR.0000000000000455","DOI":"10.1161\/CIR.0000000000000474"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0014","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.cell.2006.12.036","article-title":"A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy","volume":"128","author":"Hilfiker-Kleiner","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0015","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1479-828X.1998.tb02977.x","article-title":"Fatal myocardial infarction associated with bromocriptine for postpartum lactation suppression","volume":"38","author":"Dutt","year":"1998","journal-title":"Aust New Zeal J Obstet Gynaecol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0016","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1471-0528.1976.tb00912.x","article-title":"Serum prolactin and the suppression of lactation","volume":"83","author":"Weinstein","year":"1976","journal-title":"BJOG An Int J Obstet Gynaecol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0017","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCULATIONAHA.120.052395","article-title":"Genetic and phenotypic landscape of peripartum cardiomyopathy","author":"Goli","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0018","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1505517","article-title":"Shared genetic predisposition in peripartum and dilated cardiomyopathies","volume":"374","author":"Ware","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0019","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00395-015-0517-2","article-title":"Evidence of autoantibodies against cardiac troponin I and sarcomeric myosin in peripartum cardiomyopathy","volume":"110","author":"Haghikia","year":"2015","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1161\/CIRCULATIONAHA.109.895458","article-title":"Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension","volume":"122","author":"Noori","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0021","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1161\/HYPERTENSIONAHA.111.182170","article-title":"Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia","volume":"59","author":"Rajakumar","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0022","first-page":"349","article-title":"Low STAT3 expression sensitizes to toxic effects of \u03b2-adrenergic receptor stimulation in peripartum cardiomyopathy","volume":"38","author":"Stapel","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2265.2002.01638.x","article-title":"Oxidative stress and normal pregnancy","volume":"57","author":"Toescu","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0024","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/cvr\/cvu010","article-title":"Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress","volume":"101","author":"Ricke-Hoch","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0025","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1161\/CIRCULATIONAHA.109.901496","article-title":"Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: A proof-of-concept pilot study","volume":"121","author":"Sliwa","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0026","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/endo-129-2-896","article-title":"The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells","volume":"129","author":"Ferrara","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0027","first-page":"1380","article-title":"A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells","volume":"130","author":"Clapp","year":"1992","journal-title":"Endocrinology"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0028","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1677\/joe.0.1730219","article-title":"Roles of prolactin and related members of the prolactin\/growth hormone\/placental lactogen family in angiogenesis","volume":"173","author":"Corbacho","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0029","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1210\/me.13.5.692","article-title":"16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells","volume":"13","author":"D'Angelo","year":"1999","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0030","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1172\/JCI64365","article-title":"MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy","volume":"123","author":"Halkein","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0031","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1152\/ajpheart.00385.2010","article-title":"Activation of the neuregulin\/ErbB system during physiological ventricular remodeling in pregnancy","volume":"300","author":"Lemmens","year":"2011","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0032","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1210\/me.2004-0515","article-title":"The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G 2-M phases","volume":"19","author":"Tabruyn","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0033","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1073\/pnas.89.22.10686","article-title":"In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis","volume":"89","author":"Bacharach","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0034","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0950-3536(05)80188-X","article-title":"2 Endothelial cell proteases: physiological role and regulation","volume":"6","author":"Menashi","year":"1993","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0035","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1210\/endo.139.9.6194","article-title":"Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression","volume":"139","author":"Lee","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0036","doi-asserted-by":"crossref","first-page":"11045","DOI":"10.1158\/0008-5472.CAN-07-0986","article-title":"16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway","volume":"67","author":"Lee","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0037","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1210\/en.2004-0647","article-title":"16K-prolactin inhibits activation of endothelial nitric oxide synthase, intracellular calcium mobilization, and endothelium-dependent vasorelaxation","volume":"145","author":"Gonzalez","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0038","doi-asserted-by":"crossref","first-page":"7984","DOI":"10.1158\/0008-5472.CAN-05-0631","article-title":"16-kDa prolactin down-regulates inducible nitric oxide synthase expression through inhibition of the signal transducer and activator of transcription 1\/IFN regulatory factor-1 pathway","volume":"65","author":"Lee","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0039","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1210\/me.2003-0132","article-title":"The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-\u03baB","volume":"17","author":"Tabruyn","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0040","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1210\/mend.14.10.0543","article-title":"The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation","volume":"14","author":"Martini","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0041","unstructured":"Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation. 2022."},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0042","unstructured":"Qualtrics XM \/\/The Leading Experience Management Software. https:\/\/www.qualtrics.com\/au\/?rid=ip&prevsite=en&newsite=au&geo=IN&geomatch=au. Accessed November 17, 2021."},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0043","first-page":"198","volume":"113","author":"Wells","year":"1993","journal-title":"Newcastle-Ottawa scale"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0044","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0045","series-title":"Stata Statistical Software: Release 16","year":"2019"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0046","first-page":"1098","article-title":"Bromocriptine in management of peripartum cardiomyopathy: a randomized study on 96 women in Burkina Faso","volume":"5","author":"Yam\u00e9ogo","year":"2017","journal-title":"J Cardiol Clin Res"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0047","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehx355","article-title":"Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study","volume":"38","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0048","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ehf2.12376","article-title":"The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the BRO-HF retrospective cohort study","volume":"6","author":"Tremblay-Gravel","year":"2019","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0049","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ejhf.882","article-title":"Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome","volume":"19","author":"Ersb\u00f8ll","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0050","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/14767058.2018.1494146","article-title":"Predictors of early and delayed recovery in peripartum cardiomyopathy: a prospective study of 52 Patients","volume":"33","author":"Biteker","year":"2020","journal-title":"J Matern Neonatal Med"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0051","doi-asserted-by":"crossref","DOI":"10.1007\/s00395-013-0366-9","article-title":"Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy","volume":"108","author":"Haghikia","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0052","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/ejhf.808","article-title":"Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy","volume":"19","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0053","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ehf2.12553","article-title":"Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers","volume":"7","author":"Azibani","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0054","doi-asserted-by":"crossref","first-page":"58","DOI":"10.18087\/cardio.2020.6.n984","article-title":"The effect of bromocriptine on clinical and laboratory parameters in patients with peripartum cardiomyopathy","volume":"60","author":"Kurbanov","year":"2020","journal-title":"Kardiologiya"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(02)00008-9","article-title":"The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy","volume":"4","author":"Sliwa","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0056","first-page":"598","article-title":"Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy","volume":"113","author":"Nonhoff","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00073","article-title":"Prolactin and autoimmunity","volume":"9","author":"Borba","year":"2018","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101461_bib0058","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18773\/austprescr.2020.022","article-title":"Treatment of systemic lupus erythematosus","volume":"43","author":"McKeon","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0059","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s10741-021-10185-8","article-title":"Effects of bromocriptine in peripartum cardiomyopathy: a systematic review and meta-analysis","volume":"27","author":"Trongtorsak","year":"2022","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0060","unstructured":"McNamara DM. Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05180773. Accessed February 20, 2022."},{"key":"10.1016\/j.cpcardiol.2022.101461_bib0061","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/edrv.22.6.0451","article-title":"Dopamine as a prolactin (PRL) inhibitor","volume":"22","author":"Ben-Jonathan","year":"2001","journal-title":"Endocr Rev"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622003589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:58:51Z","timestamp":1758938331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622003589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0146280622003589"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101461","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolactin Inhibition in Peripartum Cardiomyopathy: Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101461","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101461"}}